Medicare

October 20, 2020October 20, 2020

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

News

Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any ... Read more

February 20, 2020February 20, 2020

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

News

Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives of men with metastatic castration-resistant prostate cancer (mCRPC) in ... Read more

October 1, 2018

Prostate Cancer Diagnosis, Treatment in Older Men Incurs Needless Medicare Costs, Study Shows

News

Prostate cancer patients age 70 or older are unlikely to die of the disease, but Medicare is spending nearly $400 million annually on detection and treatment in these men, a study ... Read more

June 2, 2017June 2, 2017

Medicare Expands Coverage of Prolaris, Genetic Test for Prostate Cancer Aggressiveness

News

Medicare coverage for Prolaris genetic test, a tool developed by Myriad Genetics to help predict the aggressiveness of prostate, cancer has been expanded to include patients with favorable intermediate-risk cancer. Men with low- ... Read more

October 21, 2014October 21, 2014

Medicare Partially Covers Genetic Prostate Cancer Test

News

Medicare is starting to cover genetic prostate cancer tests and is considering the possibility to expand the coverage to a national level. The U.S. national health care program is going to ... Read more